Analysis reveals the impact of evergreening on patient access in pharmaceuticals, suggesting mixed outcomes for innovation and profitability.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Pattnaik et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: